unanswered questions about the Redux (dexfenfluramine) and Pondimin (fenfluramine) withdrawal
October 1997
There are lots of unanswered questions about the Redux (dexfenfluramine) and Pondimin (fenfluramine) withdrawal.
Preliminary tests suggest that 30% of patients on Redux or Pondimin might have damaged heart valves. There are also concerns about pulmonary hypertension and possible neurotoxicity.
These problems might be due to too much serotonin.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote